- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty
- Drug · Procedure
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 98
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ocular Hypertension
- Interventions
- bimatoprost/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 520 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Scars, Hypopigmented Scar, Hypopigmented Skin, Burn Scar, Scarring, Cicatrix, Hypertrophic, Cicatrix, Pigmentation Disorder, Burns Laser
- Interventions
- Bimatoprost, Saline
- Drug
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution, bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Primary Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
- Drug · Device
- Lead sponsor
- ForSight Vision5, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Artesia, California • La Jolla, California • Newport Beach, California + 7 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost SR, Standard of Care
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 66
- States / cities
- Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more
- Conditions
- Open Angle Glaucoma, Ocular Hypertension
- Interventions
- OTX-TIC low dose Travoprost Intracameral Implant, OTX-TIC high dose Travoprost Intracameral Implant, Durysta, Bimatoprost Intracameral Implant 10 µg
- Drug
- Lead sponsor
- Ocular Therapeutix, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 30
- States / cities
- Dothan, Alabama • Huntington Beach, California • Irvine, California + 27 more
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Interventions
- Bimatoprost Solution 1, Bimatoprost Solution 2, Bimatoprost Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Fridley, Minnesota
- Conditions
- Glaucoma
- Interventions
- bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 2 Months to 17 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Ocular Hypertension
- Interventions
- bimatoprost/timolol fixed combination
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 541 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 1
- States / cities
- Ogden, Utah
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost /timolol formulation A fixed combination ophthalmic solution, bimatoprost/timolol fixed combination ophthalmic solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Migraine Disorders, Headache Disorders
- Interventions
- Bimatoprost Topical Solution, Control
- Drug
- Lead sponsor
- Manistee Partners
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Warwick, Rhode Island
- Conditions
- Glaucoma, Open-Angle, Glaucoma; Drugs
- Interventions
- dorzolamide/timolol
- Drug
- Lead sponsor
- CT Glaucoma Associates
- Other
- Eligibility
- 25 Years to 90 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Norwalk, Connecticut
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Interventions
- bimatoprost Formulation A, bimatoprost Formulation B, bimatoprost Formulation C
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Hypotrichosis
- Interventions
- Bimatoprost 0.03% solution, Vehicle solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost 20 µg generation 2, bimatoprost 15 µg generation 2, bimatoprost 10 µg generation 2, bimatoprost 6 µg generation 2, bimatoprost 15 µg generation 1, bimatoprost 10 µg generation 1, bimatoprost 0.03%
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 36
- States / cities
- Artesia, California • La Jolla, California • Los Angeles, California + 31 more
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost 0.03% Formulation B Ophthalmic Solution, Bimatoprost 0.03% Ophthalmic Solution
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 597 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Glaucoma, Ocular Hypertension
- Interventions
- bimatoprost eye drops, placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Glaucoma
- Interventions
- Bimatoprost 0.03%, Travoprost 0.004%
- Drug
- Lead sponsor
- Innovative Medical
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Alopecia Areata
- Interventions
- Latanoprost (Xalatan), Bimatoprost (Lumigan), Topical application of latanoprost solution to eyelid
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Graves Ophthalmopathy
- Interventions
- Bimatoprost Ophthalmic
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Nail Growth Cessation, Intraocular Pressure
- Interventions
- Bimatoprost 0.01%, Placebo: saline
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Glenview, Illinois